Physician profile
Stanley G Smith
NPI 1326144114
$1,405.85
in general payments reported to CMS, 2019-2025
18 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $88.93 · 2021: $277 · 2022: $165 · 2023: $169 · 2024: $239 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $673.44 | 2019-2025 | Eysuvis, Clareon, Ngenuity |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $155.62 | 2019-2021 | |
| Horizon Therapeutics Plc | $77.12 | 2021 | |
| Mallinckrodt Hospital Products INC. | $71.17 | 2024-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $43.66 | 2019-2023 | Cequa |
| Abbvie INC. | $43.21 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Carl Zeiss Meditec USA, INC. | $42.54 | 2024 | Cirrus Hd-Oct |
| Bausch & Lomb Americas INC. | $42.36 | 2022-2023 | Vyzulta |
| Biotissue Holdings INC. | $36.32 | 2019-2020 | |
| Dompe US, INC. | $31.51 | 2024-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $31.21 | 2019 | |
| Reflow Medical INC | $30.80 | 2024 | |
| Omeros Corporation | $30.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.64 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $22.36 | 2025 | Xdemvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $15.74 | 2021 | |
| Allergan, INC. | $14.79 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.